- Home
- EXFY vs IKT Comparison
EXFY vs IKT Comparison
Compare EXFY & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXFY
- IKT
- Stock Information
- Founded
- EXFY 2008
- IKT 2008
- Country
- EXFY United States
- IKT United States
- Employees
- EXFY N/A
- IKT N/A
- Industry
- EXFY Computer Software: Prepackaged Software
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- EXFY Technology
- IKT Health Care
- Exchange
- EXFY Nasdaq
- IKT Nasdaq
- Market Cap
- EXFY 165.4M
- IKT 140.5M
- IPO Year
- EXFY 2021
- IKT 2020
- Fundamental
- Price
- EXFY $1.80
- IKT $1.75
- Analyst Decision
- EXFY Strong Buy
- IKT Buy
- Analyst Count
- EXFY 3
- IKT 2
- Target Price
- EXFY $4.75
- IKT $8.00
- AVG Volume (30 Days)
- EXFY 721.2K
- IKT 110.3K
- Earning Date
- EXFY 08-07-2025
- IKT 08-14-2025
- Dividend Yield
- EXFY N/A
- IKT N/A
- EPS Growth
- EXFY N/A
- IKT N/A
- EPS
- EXFY N/A
- IKT N/A
- Revenue
- EXFY $144,251,000.00
- IKT N/A
- Revenue This Year
- EXFY $7.77
- IKT N/A
- Revenue Next Year
- EXFY $5.45
- IKT N/A
- P/E Ratio
- EXFY N/A
- IKT N/A
- Revenue Growth
- EXFY 4.13
- IKT N/A
- 52 Week Low
- EXFY $1.60
- IKT $1.12
- 52 Week High
- EXFY $4.13
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- EXFY 35.99
- IKT 50.99
- Support Level
- EXFY $1.75
- IKT $1.61
- Resistance Level
- EXFY $1.92
- IKT $1.88
- Average True Range (ATR)
- EXFY 0.13
- IKT 0.16
- MACD
- EXFY -0.01
- IKT 0.02
- Stochastic Oscillator
- EXFY 30.77
- IKT 72.04
About EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.